Fostamatinib
Tavalisse, Tavlesse (fostamatinib) is a small molecule pharmaceutical. Fostamatinib was first approved as Tavalisse on 2018-04-17. It is used to treat thrombocytopenia in the USA. It has been approved in Europe to treat thrombocytopenia. Tavalisse's patent is valid until 2032-07-27 (FDA).
| Trade Name | Tavlesse |
|---|---|
| Common Name | Fostamatinib |
| Indication | thrombocytopenia |
| Drug Class | Tyrosine kinase inhibitors; phosphoro-derivatives |
